<![CDATA[<body bgcolor="#FFFFFF" text="#000000">
Some of the key markets in Latin America / Brazil are:
Click the links below for details of each country :
Brazil
Bolivia
Haiti
Peru
Trinidad & Tobago
Brazil, with sales of USD 7 billion, is the largest pharmaceutical market in South America and is the world's eleventh largest pharmaceutical market. It is one of the most attractive semi-regulated markets, which offer immense opportunities for speciality pharmaceutical companies like Glenmark. The company with its portfolio of existing generic products as well as new products in the pipeline would be uniquely poised to leverage the potential opportunities in this market. Glenmark Farmaceutica Ltda [GFL], a wholly owned Brazilian subsidiary of Glenmark Pharmaceuticals Ltd, was set up in Sao Paulo towards the end of 2003.
To assist in building a strong presence in the Brazilian market, GFL acquired Laboratorios Klinger in 2004 for a consideration of USD 5.2 million. Klinger is a leading, privately owned Brazilian company with a work force of 176 employees, including a sales force of 91 sales representatives. It has 21 approved product registrations in Brazil. Klinger has its own ANVISA approved manufacturing facility in Sao Bernardo do Campo in Greater Sao Paulo that manufactures solid orals [tablets, coated tablets, etc.], external semi solids [creams, gels, lotions] and liquid orals [oral suspensions, solutions, etc.]. The company's main business is generated from branded generics, with some OTC presence in the form of Ceklin [Vitamin C], which is one of the top products of the company. GFL also added 3 new brands to its portfolio in the last quarter of FY05.
In March 2005, GFL purchased a leading hormonal brand, Uno-Ciclo from Instituto Biochimico Indústria Farmacêutica Ltda. [Biochimico] for USD 4.6 million. The brand generated sales of USD 3.1 mn in Brazil in the 12 months prior to the acquisition. GFL has acquired the trademark along with exclusive manufacturing and marketing rights globally. As part of the agreement, Biochimico will contract manufacture the product for GFL. GFL will initially market the brand in Brazil and will work on extending the coverage to other Latin American markets in the course of time.
Glenmark entered this price-sensitive market in 2004. Notwithstanding stiff competition from local Latin American companies, Glenmark has established itself in the dermatological and gynaecological therapeutic segments
Haiti is the second Latin American market that Glenmark entered in 2004. Characterized by political instability, it offers a good business opportunity and Glenmark has already made its mark with its dermatological and gynaecological products.
Glenmark has been present in Peru since 2003 and is highly regarded for its dermatological and gynaecologic range of products.
Glenmark's presence in the Trinidad and Tobago Islands dates back to more than a decade, with the Candid B cream a household name. Glenmark also supplies a substantial range of products to government tenders. Through Trinidad, the company has its product presence in other Caribbean islands namely, Dominica and St. Lucia.
</body>]]>